Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹1,388Cr
Rev Gr TTM
Revenue Growth TTM
14.39%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

PUNJABCHEM
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | -24.6 | 3.4 | -13.1 | -17.8 | 0.8 | -13.9 | 0.0 | -0.1 | 2.9 | 31.9 | 5.4 | 15.3 |
| 174 | 244 | 207 | 188 | 183 | 215 | 217 | 195 | 177 | 285 | 229 | 217 |
Operating Profit Operating ProfitCr |
| 10.8 | 13.4 | 14.6 | 12.2 | 6.7 | 11.4 | 10.6 | 9.0 | 12.6 | 10.8 | 10.3 | 12.0 |
Other Income Other IncomeCr | 1 | 0 | 2 | 1 | 1 | 1 | 2 | 0 | -4 | 4 | 6 | 0 |
Interest Expense Interest ExpenseCr | 7 | 4 | 7 | 7 | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 4 |
Depreciation DepreciationCr | 5 | 5 | 6 | 5 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 7 |
| 10 | 29 | 25 | 15 | 4 | 18 | 17 | 8 | 10 | 28 | 22 | 19 |
| 7 | 8 | 7 | 4 | 1 | 5 | 4 | 2 | 3 | 7 | 3 | 5 |
|
Growth YoY PAT Growth YoY% | -83.5 | 7.9 | 3.1 | -44.2 | -24.7 | -38.5 | -31.7 | -45.8 | 192.5 | 53.5 | 49.9 | 127.5 |
| 1.6 | 7.8 | 7.5 | 5.2 | 1.2 | 5.5 | 5.1 | 2.8 | 3.5 | 6.5 | 7.3 | 5.6 |
| 2.6 | 17.8 | 14.8 | 8.2 | 2.0 | 11.0 | 10.1 | 5.0 | 5.8 | 16.8 | 15.1 | 11.3 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | -4.8 | -2.5 | -6.0 | 30.4 | -14.5 | 23.4 | 37.6 | 7.8 | -7.2 | -3.6 | 13.7 |
| 518 | 497 | 510 | 452 | 577 | 507 | 583 | 794 | 884 | 821 | 801 | 908 |
Operating Profit Operating ProfitCr |
| 8.4 | 7.6 | 2.8 | 8.4 | 10.3 | 7.7 | 14.1 | 15.0 | 12.2 | 12.1 | 11.0 | 11.3 |
Other Income Other IncomeCr | 21 | 40 | 13 | 14 | -2 | 13 | 2 | 1 | 3 | 3 | -3 | 6 |
Interest Expense Interest ExpenseCr | 35 | 50 | 31 | 18 | 17 | 18 | 13 | 12 | 18 | 21 | 18 | 17 |
Depreciation DepreciationCr | 19 | 17 | 16 | 14 | 19 | 15 | 15 | 17 | 19 | 22 | 25 | 26 |
| 14 | 14 | -19 | 24 | 29 | 22 | 69 | 112 | 89 | 73 | 54 | 79 |
| 1 | 1 | 1 | 7 | 12 | 11 | 20 | 28 | 28 | 20 | 15 | 18 |
|
| | -4.0 | -250.1 | 186.2 | -2.2 | -36.0 | 356.6 | 70.0 | -26.8 | -12.3 | -27.3 | 54.2 |
| 2.5 | 2.5 | -3.8 | 3.5 | 2.6 | 2.0 | 7.2 | 8.9 | 6.1 | 5.7 | 4.3 | 5.9 |
| 11.6 | 10.8 | -16.0 | 14.0 | 13.7 | 8.8 | 40.0 | 68.1 | 49.8 | 43.7 | 31.8 | 49.0 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| -47 | 49 | 46 | 62 | 79 | 85 | 132 | 213 | 268 | 318 | 352 | 388 |
Current Liabilities Current LiabilitiesCr | 328 | 231 | 296 | 214 | 243 | 227 | 213 | 250 | 245 | 237 | 345 | 223 |
Non Current Liabilities Non Current LiabilitiesCr | 188 | 165 | 84 | 68 | 37 | 69 | 93 | 82 | 91 | 73 | 91 | 70 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 206 | 183 | 180 | 158 | 171 | 196 | 233 | 323 | 362 | 377 | 522 | 403 |
Non Current Assets Non Current AssetsCr | 277 | 275 | 259 | 198 | 200 | 198 | 218 | 235 | 254 | 262 | 279 | 289 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 57 | 105 | 62 | 61 | 68 | 34 | 45 | 34 | 58 | 30 | 25 |
Investing Cash Flow Investing Cash FlowCr | 10 | 11 | -8 | -15 | -21 | -14 | -8 | -27 | -36 | -36 | -30 |
Financing Cash Flow Financing Cash FlowCr | -72 | -141 | -61 | -43 | -4 | -19 | -26 | -11 | -20 | 4 | 12 |
|
Free Cash Flow Free Cash FlowCr | 54 | 114 | 48 | 41 | 42 | 9 | 17 | 2 | 22 | -1 | -8 |
| 415.0 | 788.0 | -313.4 | 357.4 | 407.4 | 320.6 | 90.7 | 41.1 | 95.3 | 55.8 | 64.8 |
CFO To EBITDA CFO To EBITDA% | 121.2 | 257.2 | 419.0 | 147.5 | 103.0 | 81.2 | 46.6 | 24.6 | 47.5 | 26.4 | 25.4 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 225 | 170 | 342 | 477 | 848 | 370 | 1,073 | 1,786 | 1,015 | 1,205 | 1,139 |
Price To Earnings Price To Earnings | 15.9 | 12.8 | 0.0 | 27.8 | 50.5 | 34.4 | 21.9 | 21.4 | 16.6 | 22.5 | 29.3 |
Price To Sales Price To Sales | 0.4 | 0.3 | 0.7 | 1.0 | 1.3 | 0.7 | 1.6 | 1.9 | 1.0 | 1.3 | 1.3 |
Price To Book Price To Book | -6.5 | 22.2 | 5.9 | 6.4 | 9.3 | 3.8 | 7.4 | 7.9 | 3.6 | 3.6 | 3.1 |
| 9.7 | 7.9 | 30.6 | 13.8 | 14.1 | 10.7 | 11.9 | 13.4 | 8.9 | 11.6 | 13.0 |
Profitability Ratios Profitability Ratios |
| 48.6 | 50.2 | 47.4 | 40.3 | 37.9 | 40.8 | 40.3 | 39.0 | 36.8 | 38.7 | 40.3 |
| 8.4 | 7.6 | 2.8 | 8.4 | 10.3 | 7.7 | 14.1 | 15.0 | 12.2 | 12.1 | 11.0 |
| 2.5 | 2.5 | -3.8 | 3.5 | 2.6 | 2.0 | 7.2 | 8.9 | 6.1 | 5.7 | 4.3 |
| 23.2 | 29.2 | 6.5 | 23.9 | 25.4 | 21.6 | 37.6 | 38.9 | 28.5 | 20.7 | 13.4 |
| -40.0 | 21.7 | -34.1 | 23.2 | 18.5 | 11.0 | 34.0 | 37.0 | 21.8 | 16.2 | 10.7 |
| 2.9 | 2.9 | -4.5 | 4.8 | 4.5 | 2.7 | 10.9 | 15.0 | 9.9 | 8.4 | 4.9 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Punjab Chemicals & Crop Protection Ltd. (PCCPL), established in 1975 as *Punjab United Pesticides & Chemicals Limited* through a joint venture with Excel Industries and PSIDC, has evolved into a leading Indian manufacturer in agrochemicals, specialty chemicals, and industrial chemicals. Listed on Indian stock exchanges since 1978, the company has leveraged over five decades of expertise in complex chemistry to transition into a knowledge-driven Contract Research and Manufacturing Services (CRAMS) provider, serving domestic and global innovator clients.
Headquartered in India with three state-of-the-art manufacturing facilities in **Derabassi and Lalru (Punjab)** and **Pune (Maharashtra)**, PCCPL operates across multiple high-growth chemical segments, supporting a diversified international clientele. With total reactor capacity of 2000 KL and an installed production base of ~23,500 MTPA across 49.21 acres, the company is strategically expanding its footprint to capitalize on global supply chain shifts and emerging market opportunities.
---
### **Business Segments & Portfolio**
PCCPL operates through **four core divisions**, each backed by dedicated R&D, manufacturing, and technical infrastructure:
1. **Agrochemicals/Intermediates**
- Key products: Herbicides, fungicides, insecticides, patented and in-house developed molecules (e.g., Metamitron, Metconazole, Diflufenican).
- Focus: Niche, multi-step complex chemistry for MNCs and mid-sized agro firms.
- Over 60% of revenue contribution, with growing export orientation.
2. **Specialty & Performance Chemicals**
- Includes high-value intermediates, active pharmaceutical ingredients (APIs), and fine chemicals.
- Products from in-house R&D and CRAMS contracts.
- Strategic growth area with rising revenue share from non-agro sectors.
3. **Pharmaceuticals**
- Entry via acquisition of **Alpha Drug India Limited (2003)**.
- Manufactures niche APIs and intermediates (e.g., Albendazole, Etoricoxib, Aminoacetonitrile) under cGMP standards.
- CRAMS focus with exclusivity and long-term client partnerships.
4. **Industrial Chemicals**
- Pune facility: Sole Indian producer of food-grade phosphoric acid via thermal process.
- Offers phosphates, P₂O₅, customized oxalates, and gallic acid derivatives.
- Supplies to beverage and pharmaceutical industries with FSSC 22000 and FSSAI certifications.
---
### **CRAMS Strategic Shift & Business Model**
Since a deliberate pivot in **2016**, and further accelerated from **2022**, PCCPL has repositioned itself as a **preferred CRAMS (Contract Research and Manufacturing Services)** partner globally. The CRAMS segment now contributes over **65% of total revenue** and has emerged as the primary growth engine.
- **Business Models Offered**:
- End-to-end development: R&D → Commercial Production.
- Technology transfer + Contract Manufacturing.
- Joint CAPEX partnerships with exclusive, long-term contracts.
- **Value Proposition**:
- Fast turnaround, quality, safety, IP protection.
- Cost-competitive manufacturing through process efficiency and backward integration.
- Client-funded capital expansions, reducing financial risk.
- **Target Clients**:
- Global agrochemical MNCs (e.g., **Bayer, Nippon Kayaku, Nissan Chemical, Kureha**).
- Domestic leaders (**Lupin, Laurus Labs, Zydus Cadila**).
- Specialty chemical innovators seeking alternatives to Chinese suppliers.
---
### **Core Strengths & Capabilities**
- **Technical Expertise**: Mastery in over **20 advanced chemical processes**, including:
- Chlorination, bromination, nitration, photochlorination.
- Cryogenic and high-pressure reactions.
- Heterocyclic synthesis, hydrazine, benzylation, oxidation, azotisation.
- Phosphorus-based and halogenation chemistry.
- **R&D & Innovation**:
- Two **dedicated R&D centers** (Derabassi & Lalru) with kilo labs and pilot plants.
- Team of **30+ scientists**, including PhDs; expected to double by FY26.
- Pipeline of **25+ products**, with ~8 in active development.
- 40% of new business inquiries from **non-agrochemical sectors**, signaling diversification success.
- **Manufacturing Excellence**:
- Integrated, efficient, and scalable processes.
- ISO 9001:2015, ISO 14001:2015 (environmental), FSSC 22000 (food safety) certified.
- **Surplus capacity** across sites; current utilization at Derabassi (~81–85%), Lalru (~58%), Pune (>95%).
- **Low-Cost Producer**: Achieved through backward integration, lean processes, and engineering efficiency, enhancing export competitiveness.
---
### **Financial & Operational Highlights (Recent Years)**
- **FY2023**: Achieved record turnover of **₹1,000 crores (INR 10 billion / USD 120 million)**.
- **FY2022**: Revenue of **₹933 crores**, EBITDA of **₹140 crores**, PAT of **₹84 crores**.
- **FY2021**: Highest EBITDA in a decade at **₹97.3 crores**, driven by higher-margin CRAMS orders.
- **CAGR (4 years)**: Revenue **~17.1%**, PAT **~48.4%**.
- **Debt-to-Equity**: Improved from **1.4x (FY2018)** to **<0.4x (FY2023)** – strong financial health.
---
### **Key Partnerships & Market Positioning**
- **Strategic MOUs**: Signed **three exclusive agreements** with overseas clients for high-value agrochemicals in Japanese and European markets.
- **Global Clientele**: Includes **Bayer, Zydus, Laurus Labs, Lupin, Nippon Kayaku, Kureha, Nissan Chemical**, and others.
- **Trusted CRAMS Partner**: Known for **reliability, scalability, and technical agility**, with consistent order renewal and long-term client stickiness.